A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)

This clinical trial employed a single-center, open-label, single-arm design. A total of 80 participants aged 10 to 60 years were enrolled and divided into two age groups: 40 in the 18-60 years cohort and 40 in the 10-17 years cohort. All participants received the lyophilized human rabies vaccine (human diploid cell)

NCT Number	NCT07338786
Lead Sponsor	Changchun BCHT Biotechnology Co.
Conditions	RabiesPrevention
Enrollment	80 participants
Start Date	2025-09-13
Primary Completion	2026-01-04 (estimated)
Study Completion	2026-05 (estimated)
Updated on ClinicalTrials.gov	2026-01-14